Examination and dealing of a rare disease become complicated because of the fact that many health care providers may have controlled involvement with the identification of the particular disease condition with the diagnosis of rare diseases. Analysis before diagnosis early stage in the disease can be challenging. Specialists in the field have utilized new advances and the developing exploratory comprehension of multiple rare diseases to develop and diagnose ground breaking therapies over the last 10 years. Previously more than 230 new orphan medical drugs were approved by the U.S. Food and Drug Administration (FDA). In 2015 alone, about half (47%) of novel recent drug approvals were for rare diseases. Disease specific therapies need to be developed for productive results in treatment of Rare Diseases.